Intelligence · Clinical Development
Pipeline search results
Programs matching “trastuzumab” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 35 pipeline programs matching "trastuzumab" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
ALPELISIB for PIK3CA mutated HER2+ advanced o…
Ningbo Cancer Hospital
PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previously treated with trastuzumab
1 trial -
Trastuzumab
Hoffmann-La Roche
Metastatic Breast Cancer
1 trial -
Trastuzumab
Celltrion Healthcare Australia Pty Ltd
HER2-positive Carcinoma of Breast
1 trial -
Trastuzumab
Mylan IRE Healthcare Limited
Breast Cancer
1 trial -
Trastuzumab Deruxtecan
Daiichi Sankyo
Non-small Cell Lung Cancer
1 trial -
Trastuzumab Deruxtecan
AstraZeneca
Breast Neoplasms
1 trial -
Trastuzumab Deruxtecan
AstraZeneca
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial -
Trastuzumab Deruxtecan
Daiichi Sankyo
Gastric Cancer
1 trial -
Trastuzumab Deruxtecan
Daiichi Sankyo
Ovarian Cancer
1 trial -
Trastuzumab Emtansine
Hoffmann-La Roche
Metastatic Breast Cancer
1 trial -
Trastuzumab and neratinib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Early-stage Breast Cancer
1 trial -
Trastuzumab deruxtecan
AstraZeneca
Advanced or Metastatic Breast Cancer
1 trial -
Trastuzumab deruxtecan
AstraZeneca
Breast Cancer; HER2-positive; Metastatic
1 trial -
Trastuzumab emtansine
Hoffmann-La Roche
Breast Cancer
3 trials -
trastuzumab
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
2023/3668
The George Institute
Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-low defined as a score 1+ on immunohistochemistry [IHC] or as an IHC score 2+ and negative results on in situ hybridization (ISH) (cohort 2) ABC, and any hormone receptor (HR) status, who have progressed on trastuzumab deruxtecan (T-DXd). In addition to previous T-DXd, patients with HER2-pos tumors must have received prior treatment with trastuzumab (+/- pertuzumab) and taxanes and may have received T-DM1. Patients with HER2-low tumors must have received prior treatment with taxanes. Patients with HR-positive (HR+) and HER2-low tumor must have received prior treatment with endocrine therapy and CDK4/6 inhibitors.
1 trial -
NJMU-BC01
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
TRASTUZUMAB DERUXTECAN
Fondazione Telethon ETS
metastatic HER2-positive breast cancer patients
1 trial -
TRASTUZUMAB DERUXTECAN, SACITUZUMAB GOVITECAN
Ningbo Cancer Hospital
Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication.
1 trial -
Trastuzumab
KAZIA THERAPEUTICS LTD
Breast Cancer
1 trial -
Trastuzumab
United Therapeutics Europe Ltd
Metastatic Colon Adenocarcinoma
1 trial -
Trastuzumab
United Therapeutics Europe Ltd
Metastatic Colorectal Adenocarcinoma
1 trial -
Trastuzumab
PUMA BIOTECHNOLOGY, INC.
Metastatic Colorectal Cancer
1 trial -
Trastuzumab deruxtecan
AstraZeneca
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.